Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 4/20 | 0.57 |
| ▸ | KDR | P35968 | 4/20 | 0.57 |
| ▸ | FLT3 | P36888 | 4/20 | 0.57 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.40 |
| ▸ | FEN1 | P39748 | 2/20 | 0.40 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL423319 | 0.81 | KDR (0.78) | KITKDRFLT3IKBKE | |
| SCHEMBL420385 | 0.80 | KIT (0.45) | KITKDRFLT3IKBKENPC1 | |
| SCHEMBL422815 | 0.79 | KIT (0.60) | KITKDRFLT3IKBKENPC1 | |
| SCHEMBL425539 | 0.79 | KIT (0.61) | KITKDRFLT3IKBKEALDH1A1 | |
| SCHEMBL420989 | 0.77 | KDR (0.78) | KITKDRFLT3IKBKE | |
| SCHEMBL421023 | 0.77 | KDR (0.68) | KITKDRFLT3IKBKEALDH1A1 | |
| SCHEMBL27657320 | 0.76 | KDR (0.51) | KITKDRFLT3IKBKEALDH1A1 | |
| SCHEMBL27636455 | 0.76 | KIT (0.53) | KITKDRFLT3IKBKENPC1 | |
| SCHEMBL6798531 | 0.76 | KDR (0.59) | KITKDRFLT3IKBKENPC1 | |
| SCHEMBL27657354 | 0.76 | KDR (0.51) | KITKDRFLT3IKBKEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940778-B2 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBVIE INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8642776-B2 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBVIE INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130245015-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBVIE INC (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130030189-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBVIE INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8299243-B2 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBVIE INC. (US) | 2012-10-30 | — | — | US | disclosed |
| EP-2246333-B1 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBOTT LAB (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20120022253-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2012-01-26 | — | — | US | disclosed |
| US-8063091-B2 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBOTT LABORATORIES (US) | 2011-11-22 | — | — | US | disclosed |
| EP-2246333-A1 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | Abbott Laboratories (US) | 2010-11-03 | — | — | EP | disclosed |
| US-20090286784-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-11-19 | — | — | US | disclosed |
| US-7598283-B2 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBOTT LABORATORIES, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080076767-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBVIE INC. | 2008-03-27 | — | — | US | disclosed |
| US-7297709-B2 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBOTT LABORATORIES (US) | 2007-11-20 | — | — | US | disclosed |
| CN-1826324-A | Indazole, benzisoxazole and benzisothiazole kinase inhibitors | ABBOTT LAB (US) | 2006-08-30 | — | — | CN | disclosed |
| US-20050020603-A1 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBVIE INC. | 2005-01-27 | — | — | US | disclosed |
| US-20040235892-A1 | Indazole and benzisoxazole kinase inhibitors | ABBOTT LABORATORIES | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022253-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABL1, BLK, BTK | KIT 361/4885KDR 724/4885FLT3 41/4885 |
| US-20130245015-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABL1, BLK, BTK | KIT 361/4885KDR 724/4885FLT3 41/4885 |
| US-20080076767-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABL1, BLK, BTK | KIT 361/4885KDR 724/4885FLT3 41/4885 |
| US-20050020603-A1 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABL1, BLK, BTK | KIT 361/4885KDR 724/4885FLT3 41/4885 |
| US-20040235892-A1 | Indazole and benzisoxazole kinase inhibitors | ABL1, MAP3K19, MAP3K1 | KIT 238/4885KDR 800/4885FLT3 41/4885 |
| US-20090286784-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABL1, BLK, BTK | KIT 361/4885KDR 724/4885FLT3 41/4885 |
| US-20130030189-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABL1, BLK, BTK | KIT 361/4885KDR 724/4885FLT3 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.